The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

The invention relates to a testing system and related methods for detecting peritonitis or infection in peritoneal dialysate removed from a patient. The testing system can include a fluid sensor apparatus in a fluid line of a peritoneal dialysis cycler through which spent peritoneal dialysate can be pumped. The fluid sensor apparatus can detect one or more markers associated with peritonitis or infection.

The invention relates to a testing system and related methods for detecting peritonitis or infection in peritoneal dialysate removed from a patient. The testing system can include a fluid sensor apparatus in a fluid line of a peritoneal dialysis cycler through which spent peritoneal dialysate can be pumped. The fluid sensor apparatus can detect one or more markers associated with peritonitis or infection.

The present invention relates generally to the field of antigen binding proteins such as antibodies, in particular those which bind to HLA-DQ2.5:DQ2.5-glia-α1a, or which bind to HLA-DQ2.5:DQ2.5-glia-α2. The invention further relates to compositions and immunoconjugates comprising such antibodies and to methods of producing such antibodies. The invention also relates to methods and uses which employ such antibodies, for example in the treatment of celiac disease.

This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and/or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.

Methods to interrogate and modulate gut barrier integrity are provided. Methods for treating leaky gut barrier are also provided. Methods for early detection of diseases associated with inflammatory disorders. Methods to rapidly assess the effects of drugs, chemicals, nutritional supplements, vitamins, and probiotics on the integrity of the gut barrier are also provided.

Methods of diagnosing celiac disease in a subject are provided. In some embodiments, the method comprises contacting a sample of bodily fluid from the subject with an antigen comprising a recombinant or synthetic deamidated gliadin protein, wherein the deamidated gliadin protein comprises a hexamer of peptides each having the sequence of SEQ ID NO:1; and detecting an antibody from the sample that specifically binds to the antigen, thereby diagnosing celiac disease in the subject.

The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.

Methods, assays and compositions for measuring intestinal permeability in subjects are provided. The methods and assays comprise the measurement of the level of food dyes, such as FD&C Blue No. 1, in blood samples shortly after the ingestion of the compositions. The methods disclosed herein are simple, cost-effective, reproducible and sensitive.

The present invention relates to a combination of cell culture systems and microfluidic fluidic systems for use in providing a human innervated Intestine On-Chip. More specifically, in some embodiments, a microfluidic chip containing intestinal epithelial cells co-cultured with intestinal endothelial cells or intestinal muscle cells, or both, in the presence of induced neural crest cells may find use in providing an innervated Intestine-On-Chip. In some embodiments, an innervated Intestine On-Chip may be used for identifying (testing) therapeutic compounds for use in treating gastrointestinal disorders or diseases.